Astra Draco

Astra Draco is an early-stage biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of RAS-driven cancers. The company leverages proprietary insights into RAS biology to target specific mutations and states of the KRAS protein that have historically been considered undruggable. By focusing on novel binding pockets and mechanisms of action, Astra Draco aims to overcome resistance mechanisms associated with first-generation KRAS inhibitors. The company's primary mission is to deliver transformative therapies for patients with high-unmet-need solid tumors, including lung, colorectal, and pancreatic cancers.